Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
Micro Penny Stocks, Penny Stocks $0.10 & Under
»
CLBE-CALBATECH INC bio-tech
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by QuestSolver: [QB] brief recap. OS of under 37 mill and float at 770k CalbaTech is focused on providing products and platforms to the life sciences research market, both for biotech and pharmaceutical companies, as well as academic and government institutions. CalbaTech is pursuing a classic "roll-up" strategy of growth by acquisition. In addition to growth through acquisition, CalbaTech is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that CalbaTech believes will contribute breakthrough innovation in areas of biological discovery. Currently, CalbaTech contains four wholly owned subsidiaries, Molecula Research Laboratories, LLC. ("Molecula"), KD Medical, Inc. ("KD"), LifeStem, Inc. ("LifeStem") and Molecularware, Inc. ("Molecularware") that serve niche markets in the life sciences research market. Molecula and Molecularware were acquired by CTI in 2003, KD was acquired in November 2004, and LifeStem was incorporated in September 2004 to pursue opportunities in the rapidly expanding stem cell market. In order to accomplish its goals, CalbaTech is pursuing a strategy of combining products and technologies, and the companies that provide them, into the following divisions: 1) Molecular Applications; 2) Research Reagents; and 3) Cellular Therapeutics. By pursuing such a strategy, each division should produce value added and increasing returns on shareholders' investment through cross marketing of products and geographic expansion, as well as to achieve product enhancement and efficiency. CTI's business strategy is establish shareholder value by creating a significant new provider of research reagents, equipment and services to the life sciences market, primarily through acquisition of life science companies that share two or more of the following attributes: 1) They will be generating revenues; 2)They will be profitable; and 3) They will be suppliers of products and services into the pharmaceutical research market. Rather than produce pharmaceutical products that require more than $100 Million to reach the marketplace, CalbaTech companies will seek to provide the products and services used by the researchers creating pharmaceutical products. been looking at the chart for this lil puppy again this morning and still cannot believe I missed this one so long,this one should carry an average of .175 PPS with a few high spikes based on normal operations alone. http://quotes.nasdaq.com/quote.dll?page=charting&mode=basics&int raday=off&timeframe=1y&charttype=ohlc&splits=on&earnings=off&movingavera ge=None&lowerstudy=volume there are only 3 MM's in the .04's. ETRD NITE and SHWB .045,.046 and .049 6 MM's from .05 to .069 2 in the .07's and all the rest are .12 and above!! About LifeStem LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. The Company has filed a patent application for an endoscopic stem cell delivery device and is finalizing plans to launch a novel stem cell collection service. CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, LifeStem, Inc., is close to completion of its plans to offer a stem cell collection and storage service in selected markets. The stem cell market has developed sufficiently to a point that now offers vast opportunities. Potential consumers are becoming more knowledgeable about the possible benefits of stem cells and are more ready than ever to embrace new stem cell related services. "LifeStem has researched this market and believes that it has developed a novel approach to serve this rapidly growing market. We are anticipating launching our collection service no later than the first quarter of 2006, and possibly as soon as the fourth quarter of this year," said Dan Fulkerson, President of LifeStem Inc. LifeStem continues to maintain a focus on developing a novel approach to providing quality stem cells to researchers in California and believes that both its services will work in tandem. Future details will be provided after LifeStem completes patent and trademark protection. LifeStem is solely concentrating its efforts on autologous adult stem cells. Stem cells are the body's "master" cells that have the ability to grow into new healthy tissue. As a result, stem cells may have the potential to cure diabetes, heart disease, Alzheimer's disease, spinal cord injuries and many other medical conditions. Adult stem cells have shown great promise as a regenerative therapy and are free of the issues that complicate the use of embryonic stem cells. [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2